Thirteenth meeting of the industry stakeholder platform on research and development support, European Medicines Agency, Amsterdam, the Netherlands, 2 December 2024

Highlight report - 13th Industry stakeholder platform on research and development support

SMS guidance for external users

PSUSA/00002942/202406

Human medicines European public assessment report (EPAR): Ajovy, fremanezumab, Date of authorisation: 28/03/2019, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Opsumit, macitentan, Date of authorisation: 20/12/2013, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): SomaKit TOC, edotreotide, Date of authorisation: 08/12/2016, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, rivastigmine, Date of authorisation: 10/12/2009, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Rivastigmine Hexal, rivastigmine, Date of authorisation: 11/12/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Rivastigmine 1 A Pharma, rivastigmine, Date of authorisation: 11/12/2009, Revision: 19, Status: Authorised